ATLANTIC INTERNATIONAL CORP. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that ATLANTIC INTERNATIONAL CORP. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2022 | $78.7K | Apr 10, 2024 |
| FY2022 | Dec 31, 2021 | $210.0K | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $329.5K | Mar 23, 2022 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $435.88M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $442.61M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $401.37M | Mar 28, 2025 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $45.99M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $47.18M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $46.88M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $78.0K | Apr 10, 2024 |
| FY2022 | Dec 31, 2021 | $152.3K | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $158.7K | Mar 23, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($59.43M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($135.48M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($15.25M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($4.09M) | Apr 10, 2024 |
| FY2022 | Dec 31, 2021 | ($3.70M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | ($1.05M) | Mar 23, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($50.23M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($21.83M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($3.45M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($4.00M) | Apr 10, 2024 |
| FY2022 | Dec 31, 2021 | ($2.55M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | ($949.7K) | Mar 23, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $2.25M | Apr 10, 2024 |
| FY2023 | Dec 31, 2022 | $1.57M | Apr 10, 2024 |
| FY2022 | Dec 31, 2021 | $530.1K | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $331.0K | Mar 23, 2022 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $91.29M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $64.02M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $45.44M | Mar 28, 2025 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($4.40M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($5.99M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($9.08M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($3.66M) | Apr 10, 2024 |
| FY2022 | Dec 31, 2021 | ($1.99M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | ($757.9K) | Mar 23, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $66.8K | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $73.5K | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $73.7K | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $40.0K | Apr 10, 2024 |
| FY2022 | Dec 31, 2021 | $14.5K | Mar 16, 2023 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $113.23M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $119.75M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $126.67M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $8.41M | Apr 10, 2024 |
| FY2022 | Dec 31, 2021 | $10.74M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $694.0K | Mar 23, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $145.32M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $131.77M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $166.02M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $4.05M | Apr 10, 2024 |
| FY2022 | Dec 31, 2021 | $2.56M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $4.55M | Mar 23, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($32.09M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($12.02M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2023 | ($39.35M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2022 | ($27.30M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2021 | $8.18M | Apr 10, 2024 |
| FY2022 | Dec 31, 2020 | ($3.85M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2019 | ($2.83M) | Mar 23, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($194.91M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($135.48M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($61.80M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($18.51M) | Apr 10, 2024 |
| FY2022 | Dec 31, 2021 | ($14.41M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | ($10.71M) | Mar 23, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $81.1K | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $678.7K | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $1.35M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $2.18M | Apr 10, 2024 |
| FY2022 | Dec 31, 2021 | $4.02M | Mar 16, 2023 |
| FY2021 | Dec 31, 2019 | $5.9K | Mar 23, 2022 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $84.67M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $80.59M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $138.90M | Mar 28, 2025 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | (3) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | (12) | Apr 10, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 16, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | (3) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | (12) | Apr 10, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 16, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 55.71M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | 53.13M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | 25.42M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | 330,648 | Apr 10, 2024 |
| FY2022 | Dec 31, 2021 | 11.89M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | 4.86M | Mar 23, 2022 |